HCV Mutation Detail Information

Virus Mutation HCV Mutation Y93H


Basic Characteristics of Mutations
Mutation Site Y93H
Mutation Site Sentence CONCLUSION: The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region
Standardized Encoding Gene
Genotype/Subtype -
Viral Reference AB056520;AF009606;HQ912957;AFN53800;NC009827
Functional Impact and Mechanisms
Disease Hepatitis C, Chronic    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 39865060
Title Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
Author Kurniawan J,Handayu AD,Aprilicia G,Bahri DR,Hasan I
Journal Acta medica Indonesiana
Journal Info 2024 Oct;56(4):451-460
Abstract BACKGROUND: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurrence of RASs highlights the adaptability and resilience of the HCV. This highlights the importance of RASs mutation, enabling the development of new therapeutic strategies to combat these resistant strains. This study aims to determine the presence of early HCV mutations in chronic hepatitis C in Indonesia and the association between this mutation to the efficacy of sofosbuvir-daclatasvir. METHODS: We conducted a prospective longitudinal study in naive hepatitis C patient population. The virus was examined for RAS by RNA sequencing before starting treatment. RAS mutations were determined through the cut-off value of RAS mutations that contributed in the successful therapy. All patients were followed up until 12 weeks after completion of treatment to determine the sustained virological response 12 (SVR12). RESULTS: Out of the 58 patients, 9 patients (15.51%) did not achieve SVR. Only 14 patients was further analyzed to provide the association between the mutation and SVR-12 failure after sofosbuvir-daclatasvir therapy. Specifically, 2 patients with L31 mutation and one patient with L31/Y93 mutation achieved SVR. Only one patient with failure to achieve SVR and the mutation was found in Y93H region. CONCLUSION: The mutation of Y93H may contribute to treatment failure while L31A may increase the susceptibility to DAAs treatment.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.